Cat. #152433

HDAC2/3 inhibitor MI-192 Small Molecule (Tool Compound)

Cat. #: 152433

Sub-type: Inhibitor

Availability: Please enquire for quantities and pricing

Application: Promotes apoptosis of leukemia cell lines in vitro. Also attenuates IL-6 production in rheumatoid arthritis PBMCs in vitro. MI-192 (CRT0163458) shows potent activity in a number of cell lines tested using the NCI-60 cell panel. MI-192 was tested using the following NCI-60 cell lines: Leukemia cell lines: CCRF-CEM, HL-60 (TB), K-562, MOLT-4 and RPMI-8226. Colon Cancer cell lines: COLO205, HCC-2998, HCT-116, HCT-15, HT29, KM12 and SW-620. CNS Cancer cell lines: SF-268, SF-295, SF-539, SNB-19, ...

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Enquire or request a quote

Contributor

Inventor: Ron Grigg

Institute: University of Leeds

Tool Details

Handling

Target Details

Application Details

References

Tool Details

*FOR RESEARCH USE ONLY

Tool name: HDAC2/3 inhibitor MI-192 Small Molecule (Tool Compound)
Molecular formula: C24H21N3O2.HCl
Tool sub type: Inhibitor
Primary target: HDAC2/3
Description: MI-192 is a novel benzamide-based compound with marked selectivity for the class I enzymes, HDAC2 (histone-deacetylase 2) and HDAC3 (histone-deacetylase 3). MI-192 is also a histone-deacetylase (HDAC)-3 selective inhibitor. MI-192 might have potential in the treatment of rheumatoid arthritis, and HDAC-selective inhibition may improve the therapeutic margin of safety. Studies in various cancer cell lines have also revealed that MI-192 might be a potential therapeutic agent for use in leukaemia.
Application: Promotes apoptosis of leukemia cell lines in vitro. Also attenuates IL-6 production in rheumatoid arthritis PBMCs in vitro. MI-192 (CRT0163458) shows potent activity in a number of cell lines tested using the NCI-60 cell panel. MI-192 was tested using the following NCI-60 cell lines: Leukemia cell lines: CCRF-CEM, HL-60 (TB), K-562, MOLT-4 and RPMI-8226. Colon Cancer cell lines: COLO205, HCC-2998, HCT-116, HCT-15, HT29, KM12 and SW-620. CNS Cancer cell lines: SF-268, SF-295, SF-539, SNB-19, ...
Purpose: Inhibitor
Selectivity: Exhibits >250-fold selectivity for HDAC2/3 over other HDAC isoforms.
Iupac: N-(2-Amino-phenyl)-4-(4-methylene-1-oxo-3,4-dihydro-1H-isoquinolin-2-ylmethyl)-benzamide.
Molecular weight: 419.91
Solubility: DMSO

Handling

Purity: 419.91 g/mol
Storage conditions: Ambient
Shipping conditions: Dry Ice

Target Details

Primary target: HDAC2/3
Ic50: Potent and selective HDAC2/3 inhibitor (IC50 values are 16 and 30 nM, respectively)

Application Details

Application: Promotes apoptosis of leukemia cell lines in vitro. Also attenuates IL-6 production in rheumatoid arthritis PBMCs in vitro. MI-192 (CRT0163458) shows potent activity in a number of cell lines tested using the NCI-60 cell panel. MI-192 was tested using the following NCI-60 cell lines: Leukemia cell lines: CCRF-CEM, HL-60 (TB), K-562, MOLT-4 and RPMI-8226. Colon Cancer cell lines: COLO205, HCC-2998, HCT-116, HCT-15, HT29, KM12 and SW-620. CNS Cancer cell lines: SF-268, SF-295, SF-539, SNB-19, ...

References

WO2013005049 PMID: 22818799